产品说明书

Ciprofloxacin

Print
Chemical Structure| 85721-33-1 同义名 : Bay-09867
CAS号 : 85721-33-1
货号 : A208061
分子式 : C17H18FN3O3
纯度 : 98%
分子量 : 331.341
MDL号 : MFCD00185755
存储条件：

粉末 Inert atmosphere,Room Temperature

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

0.1 M HCL: 15 mg/mL(45.27 mM)，配合低频超声，水浴加热至45℃，并调节pH至2
动物实验配方：
生物活性
靶点

  • Topo IV
描述 Ciprofloxacin is a potent, orally active topoisomerase IV inhibitor. Ciprofloxacin has anti-proliferative activity and induces Apoptosis. Ciprofloxacin is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity. Ciprofloxacin (5-50 μg/mL; 0-24 h; tendon cells) inhibits cell proliferation and causes cell cycle arrest at the G2/M phase[3]. Ciprofloxacin shows potent activity against Y. pestis and B. anthracis with MIC90 of 0.03 μg/mL and 0.12 μg/mL, respectively[4]. Ciprofloxacin (100 mg/kg; i.g.; daily, for 4 weeks; C57BL/6J mice) accelerates aortic root enlargement and increases the incidence of aortic dissection and rupture by decreases LOX level and increases MMP levels and activity in the aortic wall. Ciprofloxacin (100 mg/kg; i.g.; daily, for 4 weeks; C57BL/6J mice) induces DNA damage and release of DNA to the cytosol, mitochondrial dysfunction, and activation of cytosolic DNA sensor signaling. Ciprofloxacin lactate increases apoptosis and necroptosis in the aortic wall[5].
细胞研究
细胞系 浓度 检测类型 检测时间 活动说明 数据源
5637 cells Function assay 12 h Antibacterial activity against uropathogenic Escherichia coli UTI89 infected in human 5637 cells assessed as decrease in intracellular bacterial level at 2 to 3 ug/ml after 12 hrs by serial dilution method 20231390
Caco-2 cells Function assay 30 mins Antibacterial activity against wild type Salmonella enteritidis 5408 harboring gyrA D87Y mutant gene infected in human Caco-2 cells assessed as effect on bacterial cell adherence after 30 mins 19917752
CCRF-CEM cells 50 μM Proliferation assay Antiproliferative activity against human CCRF-CEM cells assessed as cell viability at 50 uM by CellTiter assay relative to DMSO control 24138941
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT02423759 Benign Prostate Hyperplasia Phase 4 Completed - Egypt ... 展开 >> Urology and Nprhology Center Mansoura, Aldakahlia, Egypt, 35516 收起 <<
NCT03716804 Uncomplicated Urinary Tract In... 展开 >>fection Antibiotic Resistant Infection 收起 << Phase 4 Recruiting January 25, 2019 Bangladesh ... 展开 >> Combined Military Hosptal, Dhaka Recruiting Dhaka, Bangladesh Contact: Abdul Quddus Bhuiyan, MBBS, FCPS    1673615641 ext +880 收起 <<
NCT01873690 Urolithiasis Phase 3 Terminated(Due to the low recr... 展开 >>uitment rate and the large number lost to follow-up) 收起 << - Canada, Ontario ... 展开 >> St. Joseph's Hospital, St. Joseph's Health Care London London, Ontario, Canada, N6A 4V2 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

3.02mL

0.60mL

0.30mL

15.09mL

3.02mL

1.51mL

30.18mL

6.04mL

3.02mL
参考文献

[1]Pan XS, Ambler J, et al. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob Agents Chemother. 1996 Oct;40(10):2321-6.

[2]Wise R, Andrews JM, et al. In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents. Antimicrob Agents Chemother. 1983 Apr;23(4):559-64.

[3]Tsai WC, Hsu CC, Tang FT, Wong AM, Chen YC, Pang JH. Ciprofloxacin-mediated cell proliferation inhibition and G2/M cell cycle arrest in rat tendon cells. Arthritis Rheum. 2008;58(6):1657-1663.

[4]Steenbergen J, Tanaka SK, Miller LL, Halasohoris SA, Hershfield JR. In Vitro and In Vivo Activity of Omadacycline against Two Biothreat Pathogens, Bacillus anthracis and Yersinia pestis. Antimicrob Agents Chemother. 2017;61(5):e02434-16.

[5]LeMaire SA, Zhang L, Luo W, et al. Effect of Ciprofloxacin on Susceptibility to Aortic Dissection and Rupture in Mice. JAMA Surg. 2018;153(9):e181804.